logo
  

Hyundai Bioscience To Request Fast Track Processing In U.S. For Monkeypox Treatment Drug

Hyundai Bioscience said it has decided to submit a request for a fast track processing to the U.S. Food and Drug Administration for CP-COV03, an oral antiviral medicine for the treatment of monkeypox, which it developed as a treatment for COVID-19.

Hundai Bioscience plans to submit data related to results of animal studies of CP-COV03 to the FDA as swiftly as possible.

Niclosamide, the active ingredient of CP-COV03, has already been shown to have excellent efficacy against monkeypox type of virus, according to a recently published research.

Hyundai Bioscience has decided to accelerate the speed of current phase 2 study of CP-COV03 for COVID-19 by expanding the number of hospitals where clinical trials take place as of next week.

Niclosamide-based CP-COV03, a cell-directed drug as opposed to other virus-directed drugs, is a broad-spectrum antiviral drug candidate that promotes cellular autophagy, which induces cells to recognize virus as foreign substance and then destroy it, which is why the scientific community considers the drug's pharmacological mechanism of action applicable to almost all types of viral infections.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Communications Commission or FCC has granted SpaceX Services, Inc. authorization to use its Starlink satellite internet system on vehicles in motion. SpaceX, owned by Elon Musk, is allowed to operate consumer and enterprise Ku-band Earth Stations in Motion or ESIM using frequencies allocated to the fixed satellite service. The approval would help the company to expand its services to Loud Muscle Science, LLC is recalling certain Launch Sequence products in the United States and Canada citing the presence of undeclared Tadalafil, the U.S. Food and Drug Administration said. These tainted Launch Sequence Capsule products are marketed as dietary supplements for male sexual enhancement. The U.S. Food and Drug Administration announced the intended availability of around 17 million bottles equivalent of general infant formula to be imported from New Zealand and Ireland. Under the FDA's enforcement discretion to source more infant formula to the U.S., French food company Danone SA will send 555,000 cans Aptamil Gold Plus from New Zealand.
Follow RTT